Drugmakers use events, meetings for promo

17 September 2000

Meetings and events continue to be an effective way to get doctors'attention, according to Scott-Levin's US Total Promotion Report Generator System Physician Meeting & Event Audit. Doctors are more likely to accept invitations to events associated with a pharmaceutical company; while physicians said yes to only 40% of invitations not associated with a manufacturer last year, they accepted 49% of those associated with a drug firm.

However, who makes the invitation matters. The audit found that pharmaceutical sales representatives extended 65% of all invitations, but physicians accepted only about half (47%) of these. Doctors were more likely to say yes when a third-party organization made the invitation on behalf of the manufacturer. In such situations, physicians accepted 59% of the time.

Wave of creativity in invitations

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight